Anemia of Inflammation in Solid Tumor Patients and Practical Education for Oncologists and Nurses Authors: Xiaoyan Si, Xiaomin Wei, Xiaoyan Liu, Mei Li, Mengzhao Wang, Li Zhang Published: 2026 ABSTRACT ABSTRACTAnemia is prevalent in patients with cancer, and anemia of inflammation (AI) is a common pathophysiological type. AI is mainly characterized by functional iron deficiency. This review summarizes the current knowledge regarding the epidemiology, clinical manifestations, molecular mechanisms, diagnostic criteria, and therapeutic advancements in cancer‐related AI. It focuses on the central role of interleukin‐6 (IL‐6) and the emerging therapeutic strategies targeting the IL‐6‐hepcidin‐ferroportin axis. Additionally, this review integrates practical educational content designed for oncologists and nurses to enhance their clinical competence in recognizing, diagnosing, and managing AI; it is essential to alleviate the symptom burden and improve the quality of life of patients with cancer. Introduction Cancer‐related anemia is caused by multiple factors, including blood loss, nutritional deficiencies, bone marrow infiltration, myelosuppressive therapies, and inflammation associated with malignancy. Anemia is an independent prognostic factor associated with shortened survival and increased morbidity in cancer patients [1]. Anemia of inflammation (AI), also known as anemia of chronic disease, is characterized by dysregulated iron homeostasis, suppressed erythropoiesis, and shortened red blood cell (RBC) lifespan [2]. This narrative review summarizes the clinical burden of AI in cancer patients, elucidates the cellular and molecular mechanisms, outlines diagnostic approaches, evaluates current and investigational therapeutic strategies, and provides practical educational frameworks for oncologists and nurses to improve clinical practice in AI management. The key studies cited were identified through systematic searches of Web of Science, PubMed, and Embase, using combinations of the following keywords: AI, anemia of chronic disease, solid tumor, and cancer. The search was limited to articles published in English between 2000 and 2026. This review aims to cover the most influential and representative literature, with a particular emphasis on recent advancements and clinical trials. Epidemiology and Clinical Manifestation Anemia affects 30%–90% of cancer patients, prevalence varying by tumor type and stage [3, 4]. About 29.3% of patients presented with mild anemia (hemoglobin 100–119 g/L), 8.7% had moderate anemia (hemoglobin 80–99 g/L), and 1.3% experienced severe anemia (hemoglobin < 80 g/L) [3]. AI accounts for 40% of anemia [5]. Patients with AI typically present with fatigue, dyspnea, dizziness, and tachycardia; some also develop fever, night sweats, decreased performance status, weight loss, and cachexia secondary to paraneoplastic inflammatory syndrome [6]. Symptoms of AI are often misattributed to the cancer itself or its treatment, leading to underdiagnosis and delayed intervention. Oncologists and nurses should receive targeted education to recognize these nonspecific symptoms as manifestations of AI. Pathophysiology Cancer‐associated AI arises primarily from a complex network of pro‐inflammatory cytokines secreted by tumor cells and tumor‐associated immune cells. Understanding these mechanisms is critical for oncologists and nurses to make diagnosis and explain AI to patients (Figure 1; Created with BioGDP.com [7]). Pathophysiology in anemia of inflammation. Tumor‐ and immune‐derived cytokines (IL‐6, IL‐1β) increase expression of hepcidin in the liver. Hepcidin inhibits ferroportin, which is the sole cellular iron exporter, and transfers iron to blood plasma. Tumor necrosis factor‐α (TNF‐α) also suppresses ferroportin expression. Transforming Growth Factor‐β (TGF‐β) and IL‐10 inhibit erythroid progenitor proliferation. Interferon‐γ (IFN‐γ) activates macrophages for erythrophagocytosis and thereby shorten the erythrocyte lifespan. Interleukin‐6 (IL‐6) IL‐6 production within tumors is driven by a complex signaling network involving multiple cell populations and pathways within the tumor microenvironment (TME). The main sources of IL‐6 include tumor cells, tumor‐associated macrophages (TAMs), cancer‐associated fibroblasts (CAFs), and other stromal cells [8]. IL‐6 expression is primarily triggered by inflammatory signals such as tumor necrosis factor‐α (TNF‐α) and interleukin‐1β (IL‐1β), which activate nuclear factor κB (NF‐κB) and other transcription factors. A core pathogenic mechanism is the IL‐6 amplifier: A positive feedback loop in which IL‐6 activates signal transducer and activator of transcription three (STAT3), which in turn enhances NF‐κB activity to sustain and amplify IL‐6 overproduction. This autocrine and paracrine loop results in a chronic inflammatory state that promotes tumor progression and therapy resistance [9]. IL‐6 activates the Janus kinase 2 (JAK2)/STAT3 signaling pathway in hepatocytes to upregulate hepcidin expression. Ferroportin is expressed on the surface of cells that release iron into the plasma, including duodenal enterocytes, macrophages, and hepatocytes. Hepcidin binds ferroportin and induces its internalization and degradation. This process impairs iron absorption in enterocytes and iron sequestration in macrophages [10, 11]. Serum IL‐6 levels correlated strongly with hepcidin concentrations and the severity of anemia in patients with solid malignancies [12]. Il‐1β IL‐1β originates from tumor‐infiltrating immune cells, such as TAMs, and the tumor cells [13]. In immune cells, it is typically triggered by pathogens or cytokines via NF‐κB signaling. IL‐1β establishes a positive feedback in the TME to amplify inflammation [14]. IL‐1β upregulates hepcidin expression [15], suppresses the formation of erythroid colonies in bone marrow, and inhibits erythropoietin (EPO) receptor signaling [16]. Tumor Necrosis Factor‐α (TNF‐α) TNF‐α is secreted by activated macrophages, lymphocytes, endothelial cells, and cancer cells in the TME [17]. TNF‐α exhibits a dual role in cancer. It can induce tumor cell apoptosis to exert anti‐tumor effects, yet it also promotes tumor proliferation, angiogenesis, and metastasis through NF‐κB and mitogen‐activated protein kinase (MAPK) signaling pathways [18]. TNF‐α suppresses ferroportin expression in AI. Besides, it inhibits erythropoietic progenitor proliferation, shortens erythrocyte lifespan, and impairs erythropoietin production [19]. Anti‐TNF‐α therapies, such as etanercept, adalimumab, and infliximab, improve hemoglobin levels in patients with rheumatoid and psoriatic arthritis [19]. Interferon‐γ (IFN‐γ) IFN‐γ is predominantly secreted by Type 1 T helper (Th1) cells, cytotoxic T lymphocytes (CTLs), and natural killer (NK) cells in the TME [20]. IFN‐γ inhibits erythroid progenitors in AI [20]. It enhances macrophage phagocytosis of senescent RBCs, thereby shortening RBC survival time [21]. Transforming Growth Factor‐β (TGF‐β) TGF‐β is overexpressed in pancreatic, breast, and other solid tumor types. TGF‐β is produced by cancer cells, CAFs, myeloid‐derived suppressor cells (DMSCs), TAMs, and regulatory T cells (Tregs) in the TME [22]. It acts as a critical negative regulator of erythropoiesis by potently inhibiting erythroid progenitor proliferation through Smad2/3‐dependent signaling while paradoxically accelerating terminal differentiation in AI, leading to cell cycle exit and apoptosis of immature erythroid precursors [23]. Interleukin‐10 (IL‐10) IL‐10 is a cytokine synthesis inhibitor produced by Type 2 T helper (Th2) cells. It is involved in broad immune‐regulatory and anti‐inflammatory activities. Activation of the IL‐10 receptor (IL‐10R) generates a signaling cascade through the JAK1‐STAT3 pathway, leading to complex effects including anti‐inflammatory, immune‐suppression, and immune‐stimulation [24]. IL‐10 plays a paradoxical dual role in the pathogenesis of AI in cancer patients. On one hand, IL‐10 alleviates iron metabolism disturbances by suppressing the IL‐6/STAT3/hepcidin axis [25]. On the other hand, IL‐10 inhibits erythroid progenitor cells, particularly burst‐forming unit‐erythroid (BFU‐E), through activation of the STAT1/IFN‐γ/IL‐15 pathway. IL‐10 promotes ferritin synthesis and iron retention within macrophages. This complex interplay shows precise dose modulation and timing when considering IL‐10‐based therapeutic strategies for cancer‐associated anemia [26]. Diagnosis and Differential Diagnosis Diagnosis of AI requires laboratory parameters of complete blood count, iron metabolism, and systemic inflammation [2]. AI must be differentiated from other causes of anemia in cancer patients, such as iron deficiency anemia and chemotherapy induced anemia (Table 1). TABLE 1Differential diagnosis of anemia of inflammation.ParameterAnemia of inflammationIron deficiency anemiaChemotherapy‐induced anemiaPrimary pathophysiologyIron sequestration (functional iron deficiency)Absolute iron deficiencyBone marrow suppressionMean corpuscular volume (MCV)NormalLowNormalMean corpuscular hemoglobin (MCH)NormalLowNormalReticulocyte countNormal or lowNormal or lowLowSerum ironLowLowNormalTotal iron‐binding capacity (TIBC)LowHighNormalSerum ferritinNormal or highVery lowNormalTransferrin saturation (TSAT)LowVery lowNormalSoluble transferrin receptor (sTfR)NormalHighNormalSerum hepcidinHighLowVariableErythropoietin (EPO)Inappropriately normal/low for the degree of anemiaNormal or HighNormal or HighInflammatory markers (C‐reactive protein, erythrocyte sedimentation rate, interleukin‐6)HighNormalNormal Differential diagnosis of anemia of inflammation. Treatment of AI Current Treatments and Associated Limitations The evidence for the treatment of inflammatory anemia is mostly derived from studies on rheumatoid arthritis (RA) and chronic kidney disease (CKD), which can provide some reference but cannot be directly applied to cancer‐related AI due to the unique characteristics of tumors. Most clinical studies and therapeutic guidelines focus on chemotherapy‐induced anemia or nutritional deficiency anemia in cancer patients, while cancer‐related AI, which has distinct pathophysiological characteristics, is often overlooked, leading to a lack of standardized treatment strategies and unclear therapeutic efficacy. Oral and intravenous iron supplementation: Oral iron formulations are generally ineffective in AI due to hepcidin‐mediated blockade of absorption. Intravenous (IV) iron administration bypasses hepcidin‐mediated blockade and improves hemoglobin (Hb) levels [27]. However, it was reported that iron supplements are ineffective in AI, and IV iron is trapped in macrophages and may enhance inflammation [28]. Erythropoiesis‐stimulating agents (ESAs): Clinical evidence supports that ESAs are effective in improving Hb levels and quality of life in AI, particularly in RA and inflammatory bowel disease (IBD) [29, 30]. However, it is restricted due to the risks of venous thromboembolism and potential tumor progression in patients with cancer. As existing studies are limited by small sample sizes, the safety profile of ESAs in cancer‐related AI requires further investigation. RBC Transfusion: RBC transfusion is reserved for patients with severe, symptomatic AI. Common adverse events include transfusion reaction, infection, and iron overload. Nurses require education on transfusion guidelines, including pre‐transfusion checks, infusion rate monitoring, and recognition of transfusion reactions. Therapeutic Advances Therapeutic strategies targeting IL‐6‐hepcidin to AI provide new treatment options (Table 2). Monoclonal antibody‐mediated IL‐6 blockade has demonstrated promising efficacy in patients with different diseases. A Phase 2 clinical trial demonstrated that ziltivekimab improved the markers of anemia and iron homeostasis in people with Stage 3–5 CKD and systemic inflammation [32, 33]. Tocilizumab and clazakizumab increased Hb in patients with cancer. However, siltuximab failed to reduce RBC transfusions in transfusion‐dependent patients with MDS [31]. Hepcidin‐targeted therapies such as PRS‐080#22 have shown lowering hepcidin and increasing iron availability in patients with CKD undergoing hemodialysis [37]. Meanwhile, hypoxia‐inducible factor prolyl hydroxylase inhibitors (HIF‐PHIs), including roxadustat, vadadustat, and daprodustat, provide a distinct approach to treat anemia. It stimulates endogenous erythropoietin production and enhances iron mobilization. A retrospective study showed that roxadustat significantly increased Hb levels in different CRP level groups with CKD [42]. TNF‐α inhibition infliximab resulted in higher hemoglobin levels in Crohn disease [41]. These advances reflect pathophysiology‐based therapies are efficacious in AI. TABLE 2Therapeutic studies on anemia of inflammation.TargetCompoundStudy typePatient populationOutcomesInterleukin‐6 (IL‐6)SiltuximabPhase 2 study [31]Myelodysplastic syndromeNot reduce red blood cell transfusionsIL‐6ZiltivekimabPhase 1/2 trial (NCT02868229) [32]Chronic kidney disease on hemodialysisReduce erythropoiesis‐stimulating agent requirementIL‐6ZiltivekimabPhase 2 clinical trial (NCT03926117) [33]Chronic kidney diseaseIncrease hemoglobin (Hb), improved iron homeostasisIL‐6TocilizumabReal world study [34, 35]Rheumatoid arthritisIncrease HbIL‐6TocilizumabRetrospective study [6]CancerIncrease HbIL‐6Clazakizumab (ALD518)Phase 2 clinical trial [36]Lung cancerIncrease HbhepcidinPRS‐080#22Phase 1 clinical trial (NCT02340572, NCT02754167) [37]Chronic kidney diseaseDecrease hepcidin, and increase ironHypoxia‐inducible factor (HIF)RoxadustatPhase 3 clinical trial [38]Chronic kidney diseaseNoninferior to ESAsHIFvadadustatPhase 3 clinical trial (NCT02865850, NCT02892149) [39]Dialysis‐dependent chronic kidney diseaseNoninferior to darbepoetin alfa with respect to correction and maintenance of hemoglobin concentrations.HIFDaprodustatPhase 3 clinical trial (NCT02879305) [40]Chronic kidney diseaseNoninferior to ESAs for increase in HbTumor necrosis factor‐αInfliximabProspective observational study [41]Crohn diseaseHigher median Hb levels Therapeutic studies on anemia of inflammation. Practical Education for Oncologists and Nurses Although AI is highly prevalent among patients with cancer, it is underrecognized and underdiagnosed in clinical practice. The current landscape of oncology education faces significant challenges in preparing healthcare professionals to diagnose and manage AI. The current curricula mainly focus on iron deficiency anemia and anemia caused by bone marrow suppression resulting from radiotherapy and chemotherapy. Consequently, clinicians and nurses receive inadequate formal training in recognizing AI. AI presents significant diagnostic challenges as it requires differentiation from bone marrow infiltration, iron deficiency anemia, or drug‐induced myelosuppression. Current education lacks structured diagnostic reasoning frameworks. We propose a competency‐based education framework for oncologists and nurses, and it is also applicable to medical students, residents, fellows, practicing clinicians, and allied health professionals. This framework is intended to equip oncologists and nurses with a comprehensive understanding of the molecular mechanisms of AI, particularly the IL‐6‐hepcidin‐ferroportin axis and the synergistic roles of other pro‐inflammatory cytokines, enhance proficiency in interpreting laboratory results (the characteristic pattern of functional iron deficiency) and applying diagnostic algorithms to distinguish AI from other types of anemia, and improve competence in selecting and administering appropriate therapies, including standard treatments and emerging targeted agents (Figure 2). Structured competency‐based education framework for oncologists and nurses in anemia of inflammation management. (1) Educational content, encompassing foundational knowledge, diagnostic competencies, evidence‐based therapeutic decision‐making, and patient‐centered care; (2) Education methods, including blended learning, interdisciplinary team‐based learning, clinical rotations in hematology‐oncology settings, and continuing education programs; (3) Evaluation of education, comprising knowledge assessments, clinical performance assessment, clinical outcome measures, and feedback‐driven program improvement. The core educational content comprises four parts: (1) mechanism‐focused knowledge, including the pathophysiology of AI; (2) diagnosis of AI from other common causes of anemia in cancer through clinical and laboratory results; (3) therapeutic decision‐making on the evidence‐based use of ESAs, iron supplementation, and blood transfusions; and (4) patient‐centered care including communication skills and symptom management. The educational delivery methods focus on the application of clinical practice. Blended learning approaches combine online modules for self‐paced learning of basic concepts and in‐person workshops for challenging case discussions, such as mixed AI/iron deficiency anemia, and AI in patients with CKD. Role‐playing exercises simulate the full diagnostic workflow, from recognizing non‐specific symptoms (fatigue, dyspnea, cognitive impairment) to ordering relevant tests (hemoglobin, ferritin, CRP, IL‐6, transferrin saturation) and interpreting results to reach a definitive diagnosis. Interdisciplinary team‐based learning sessions involve oncologists, nurses, pharmacists, and hematologists to promote collaborative care. Clinical rotations in hematology‐oncology settings for nurses and junior oncologists provide practical experience in managing AI patients. Journal clubs focus on recent clinical trials of emerging therapies, with discussions on mechanisms of action, preliminary efficacy data, safety profiles, eligibility criteria for trial participation, and how to integrate new evidence into clinical practice. Continuing education programs help update healthcare professionals on the latest research and guidelines. Visual aids and tools provide quick‐reference guides to support clinical practice and reinforce educational content. Evaluation of Educational Outcomes included knowledge assessments to evaluate understanding of AI mechanisms, diagnosis, and treatment; skills evaluations to assess proficiency in diagnostic reasoning and therapeutic decision‐making; and clinical outcome measures to evaluate the impact of education on practice. Conclusion AI in cancer is driven by cytokines that disrupt iron metabolism and erythropoiesis. While the IL‐6/hepcidin axis remains central to its pathogenesis, cytokines such as IL‐1β, TNF‐α, IFN‐γ, and TGF‐β play critical roles in amplifying the disease process. The diagnosis relies on recognizing the characteristic iron profile in inflammation. Current treatments include ESAs, IV iron, and blood transfusions, and several promising targeted therapies are being developed. Practical education for oncologists and nurses is essential to improve the recognition, diagnosis, and management of AI. By integrating mechanism‐based knowledge, diagnostic skills, treatments, and patient‐centered care into educational curricula, healthcare professionals can enhance patient outcomes and quality of life. Future management strategies will likely involve biomarker‐guided, cytokine‐targeted therapies, and ongoing education will be critical to ensure healthcare professionals improve clinical practice. Author Contributions Xiaomin Wei: conceptualization, writing – original draft. Xiaoyan Liu: writing – review and editing. Xiaoyan Si: conceptualization, writing – original draft. Mei Li: writing – review and editing. Mengzhao Wang: writing – review and editing. Li Zhang: writing – review and editing. Funding The authors have nothing to report. Disclosure No AI tools/services were used during the preparation of this work. Ethics Statement The authors have nothing to report. Conflicts of Interest The authors declare no conflicts of interest.